Dimethyltryptamine molecule:

Image from PubChem

DMT Clinical Trials

An Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics & Exploratory Efficacy of Intravenous SPL026 Drug Product (DMT Fumarate) Alone or in Combination With SSRIs in Patients With Major Depressive Disorder

To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05553691

Organisation Name: Small Pharma Ltd

Overal Status: Recruiting

Start Date: November 2022

Last Update: November 17, 2022

Lead Sponsor: Small Pharma Ltd

Brief Summary: The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.

  • Major Depressive Disorder

Total execution time in seconds: 0.33219981193542